Loading news...
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $23.15, indicating a -7.33% shift from the previous trading day.
Hims and Hers Health, Inc. (NYSE: HIMS) trended on Wednesday after the company outlined an expanded weight-management push tied to
Raul Shah from DocShah Financial shares his bullishness on top holdings, Hims & Hers (HIMS), UnitedHealth (UNH), and Gambling.com (GAMB). Tax gain harvesting and more tax takeaways for investors.
Hims & Hers expands its digital care platform with labs tracking, multi-cancer screening access and broader treatments as it scales personalized healthcare globally.
Hims and Hers Health Inc (NYSE: HIMS) shares are pulling back Monday morning, giving back a portion of last week's sharp rally.
The drama and uncertainty around Novo Nordisk and Hims and Hers Health might finally be ending.
Hims and Hers Health (NYSE: HIMS - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Valuation and Earnings This table compares
Retail investors talked up five hot stocks this week (March 9 to March 13) on X and Reddit's r/WallStreetBets, driven by retail hype, earnings, AI buzz, and corporate news flow.
Nine of the portfolio's 10 equity sectors made a positive impact on performance, with Health Care, Industrials, and Materials making the largest positive contributions. Palvella's shares appreciated significantly in 2025 as investors grew more confident in the company's pipeline following a grant from the FDA, patent wins, and a positive Phase II readout. Impinj is a long time holding in the portfolio with a very large total addressable market expansion opportunity, a strong patent portfolio, and an increasingly diversified customer base.
Hims & Hers Health, Inc. (HIMS) closed at $23.84 in the latest trading session, marking a -7.88% move from the prior day.
Expand NYSE: HIMS Hims & Hers Health Today's Change (-7.75%) $-2.00 Current Price $23.88 Key Data Points Market Cap $5.9B Day's Range $23.77 - $27.20 52wk Range $13.74 - $70.43 Volume 2.1M Avg Vol 30M Gross Margin 60.86%
HIMS is navigating margin and regulatory pressure, but new benefits, a Novo Nordisk tie-up and platform growth could drive its next move.
Shares of Eli Lilly and Company (LLY) slipped about 1% in early Thursday trading after the drugmaker cautioned about potential safety concerns tied to compounde
Hims & Hers Health ( NYSE:HIMS ) looked like a fallen growth star earlier this year.
Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate access to lucrative branded GLP-1 therapies. HIMS has demonstrated rapid revenue growth and improving profitability, with gross margins rising from 30% to nearly 75% and operating income turning positive. Valuation appears reasonable given future earnings growth potential, though current multiples are above sector averages on earnings but below on sales.
Not many things have gone right for Novo Nordisk recently, but this is one of them.
HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims and Hers Health Inc (NYSE: HIMS) higher.
Diversify Advisory Services LLC trimmed its stake in shares of Hims and Hers Health, Inc. (NYSE: HIMS) by 62.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,769 shares of the company's stock after selling 22,449 shares during the
Dimensional Fund Advisors LP lessened its holdings in shares of Hims and Hers Health, Inc. (NYSE: HIMS) by 2.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,146,977 shares of the company's stock after selling 54,789 shares during the
The Novo Nordisk partnership legitimizes Hims & Hers' business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) with $318M EBITDA and $300M operating cash flow, demonstrating strong platform economics. The company ended 2025 with 2.5M+ subscribers and $83 average monthly revenue per user, reflecting growing cross-selling across health categories.